Delving into the Latest Updates on Shanghai Joint Biosciences Ltd. with Synapse

Overview

Basic Info

Introduction

Joint Biosciences Ltd. is a pioneering company located in the Cayman Islands that specializes in developing groundbreaking combination immunotherapies for the treatment of solid tumors. As a global leader in this field, the company is dedicated to creating innovative First-in-Class medicines that can revolutionize cancer treatment.

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Digestive System Disorders

Oncolytic virus

Therapeutic vaccine

Multi-specific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	9

Top 5 Drug Type	Count

Oncolytic virus	9
Therapeutic vaccine	5
Multi-specific antibody	3

Top 5 Target	Count

CD16 x PDL1	1
CD3 x PDL1	1
PD-1 x VEGF	1
HER2(Receptor tyrosine-protein kinase erbB-2)	1
NY-ESO-1(Cancer/testis antigen 1)	1

主要目的：评估OVV-01注射液静脉和瘤内给药在晚期实体瘤受试者中的安全性和耐受性，以确定最大耐受剂量（MTD）和II期推荐剂量（RP2D）。次要目的：评估OVV-01注射液静脉和瘤内给药在晚期实体瘤受试者中的初步疗效；评估OVV-01注射液在晚期实体瘤受试者中的总体安全/耐受性；评估OVV-01注射液在晚期实体瘤受试者中的生物分布和病毒脱落情况；评估OVV-01注射液在晚期实体瘤受试者中的免疫原性；探索OVV-01注射液在外周血和肿瘤组织中可预测疗效的潜在生物标志物和血液中的细胞因子释放情况（若根据实际情况可行）。

[Translation]

Primary Objective: To evaluate the safety and tolerability of intravenous and intratumoral administration of OVV-01 injection in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and the recommended dose for Phase II (RP2D). Secondary Objectives: To evaluate the preliminary efficacy of intravenous and intratumoral administration of OVV-01 injection in patients with advanced solid tumors; to evaluate the overall safety/tolerability of OVV-01 injection in patients with advanced solid tumors; to evaluate the biodistribution and viral shedding of OVV-01 injection in patients with advanced solid tumors; to evaluate the immunogenicity of OVV-01 injection in patients with advanced solid tumors; and to explore potential biomarkers for predicting efficacy of OVV-01 injection in peripheral blood and tumor tissue, and cytokine release in the blood (if feasible).

Start Date-

Sponsor / Collaborator

Shanghai Joint Biosciences Ltd.

100 Clinical Results associated with Shanghai Joint Biosciences Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Joint Biosciences Ltd.

Login to view more data

100 Deals associated with Shanghai Joint Biosciences Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Joint Biosciences Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

5

Preclinical

Phase 2

1

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

OVV-01 ( NY-ESO-1 )	Soft Tissue Sarcoma More	Phase 2
VSV-02 ( CD3 x PDL1 )	Solid tumor More	Clinical
VSV-01 ( PD-1 x VEGF )	Solid tumor More	Clinical
OVV-2 ( CD19 )	Solid tumor More	Preclinical
OVV-5 ( TRPM1 )	Solid tumor More	Preclinical